{"url_path":"/sec/sxtp/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A RISK FACTORS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","accession_number":"0001554855-26-001058","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":191,"has_tables":true,"body_markdown":"ITEM 1A. RISK FACTORS\n\n \n\nAs a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. In any event, there have been no material changes in our risk factors as previously disclosed in our Registration Statement.\n\n \n\nIf we fail to maintain compliance with Nasdaq’s continued listing requirements, including the minimum bid price rule, our common stock could be delisted, which would adversely affect the liquidity and market price of our shares.\n\n \n\nIn January 2026, we effected a 1-for-4 reverse stock split in order to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. There can be no assurance that we will be able to maintain compliance with Nasdaq’s continued listing standards in the future. A Delisting of our common stock from The Nasdaq Capital Market would likely result in decreased liquidity for our stockholders. This could make it more difficult for us to raise additional capital, and might adversely affect the market price of our common stock."}